MARCELO FELIPE KUPERMAN BENVENISTE
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thymus Neoplasms | 9 | 2021 | 416 | 2.340 |
Why?
|
| Neoplasms, Glandular and Epithelial | 5 | 2021 | 517 | 1.740 |
Why?
|
| Diagnostic Imaging | 8 | 2021 | 1174 | 1.560 |
Why?
|
| Thymoma | 4 | 2015 | 252 | 1.070 |
Why?
|
| Tomography, X-Ray Computed | 18 | 2021 | 7787 | 1.000 |
Why?
|
| Lung Neoplasms | 16 | 2021 | 12038 | 0.980 |
Why?
|
| Radiotherapy | 3 | 2019 | 1858 | 0.950 |
Why?
|
| Lung | 9 | 2021 | 3284 | 0.920 |
Why?
|
| Mediastinal Neoplasms | 4 | 2017 | 428 | 0.900 |
Why?
|
| Thorax | 2 | 2021 | 232 | 0.820 |
Why?
|
| Radiation Injuries | 3 | 2019 | 1476 | 0.730 |
Why?
|
| Fluorodeoxyglucose F18 | 8 | 2022 | 1260 | 0.690 |
Why?
|
| Positron-Emission Tomography | 10 | 2022 | 2199 | 0.690 |
Why?
|
| Pleural Neoplasms | 3 | 2021 | 485 | 0.660 |
Why?
|
| Radiography | 3 | 2019 | 1993 | 0.630 |
Why?
|
| Lymphatic Metastasis | 6 | 2021 | 4969 | 0.600 |
Why?
|
| Positron Emission Tomography Computed Tomography | 9 | 2022 | 881 | 0.590 |
Why?
|
| Mediastinum | 2 | 2017 | 276 | 0.580 |
Why?
|
| Radiopharmaceuticals | 7 | 2022 | 1341 | 0.560 |
Why?
|
| Multimodal Imaging | 4 | 2015 | 551 | 0.550 |
Why?
|
| Thoracic Neoplasms | 3 | 2016 | 363 | 0.550 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2019 | 402 | 0.530 |
Why?
|
| Heart | 2 | 2019 | 1173 | 0.510 |
Why?
|
| Multidetector Computed Tomography | 4 | 2017 | 147 | 0.450 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2014 | 125 | 0.430 |
Why?
|
| Lipoma | 1 | 2013 | 93 | 0.430 |
Why?
|
| Breast | 2 | 2019 | 1370 | 0.420 |
Why?
|
| Mesothelioma | 1 | 2017 | 558 | 0.400 |
Why?
|
| Lymph Nodes | 6 | 2021 | 3081 | 0.380 |
Why?
|
| Image Enhancement | 2 | 2014 | 553 | 0.380 |
Why?
|
| Lung Diseases | 3 | 2014 | 751 | 0.370 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2021 | 5581 | 0.350 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2017 | 1270 | 0.350 |
Why?
|
| Esophageal Neoplasms | 5 | 2022 | 3240 | 0.330 |
Why?
|
| Neoplasm Staging | 14 | 2021 | 14021 | 0.310 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2018 | 2458 | 0.290 |
Why?
|
| Humans | 48 | 2022 | 270601 | 0.280 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2018 | 7912 | 0.270 |
Why?
|
| Adenocarcinoma | 4 | 2017 | 7919 | 0.240 |
Why?
|
| Pulmonary Embolism | 2 | 2020 | 342 | 0.230 |
Why?
|
| Pulmonary Artery | 2 | 2020 | 520 | 0.230 |
Why?
|
| Radiography, Thoracic | 2 | 2019 | 477 | 0.220 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 4964 | 0.190 |
Why?
|
| Diagnostic Errors | 2 | 2018 | 517 | 0.190 |
Why?
|
| Radiation Dosage | 2 | 2019 | 1042 | 0.190 |
Why?
|
| Artifacts | 2 | 2015 | 537 | 0.190 |
Why?
|
| Mammography | 3 | 2017 | 1055 | 0.190 |
Why?
|
| Carcinoma | 2 | 2022 | 2610 | 0.180 |
Why?
|
| Diagnosis, Differential | 7 | 2019 | 4838 | 0.180 |
Why?
|
| Thymus Gland | 1 | 2021 | 309 | 0.170 |
Why?
|
| Leukemia, Lymphoid | 1 | 2019 | 289 | 0.150 |
Why?
|
| Neoplasms | 3 | 2021 | 15931 | 0.140 |
Why?
|
| Phyllodes Tumor | 1 | 2017 | 64 | 0.140 |
Why?
|
| Bronchial Neoplasms | 1 | 2017 | 82 | 0.140 |
Why?
|
| Bevacizumab | 2 | 2018 | 967 | 0.140 |
Why?
|
| Follow-Up Studies | 4 | 2017 | 15270 | 0.140 |
Why?
|
| Fiducial Markers | 1 | 2016 | 95 | 0.130 |
Why?
|
| Bone and Bones | 1 | 2019 | 605 | 0.130 |
Why?
|
| Thrombosis | 1 | 2020 | 742 | 0.120 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2015 | 586 | 0.120 |
Why?
|
| Thoracic Wall | 1 | 2016 | 188 | 0.120 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2014 | 165 | 0.110 |
Why?
|
| Carcinoid Tumor | 2 | 2013 | 282 | 0.110 |
Why?
|
| Leukemia, Myeloid | 1 | 2019 | 993 | 0.110 |
Why?
|
| Middle Aged | 15 | 2020 | 90450 | 0.110 |
Why?
|
| Thymectomy | 1 | 2013 | 80 | 0.110 |
Why?
|
| Respiratory Tract Neoplasms | 1 | 2013 | 40 | 0.110 |
Why?
|
| Incidental Findings | 1 | 2015 | 283 | 0.110 |
Why?
|
| Male | 15 | 2020 | 128395 | 0.110 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2016 | 340 | 0.110 |
Why?
|
| Quinazolines | 1 | 2017 | 956 | 0.100 |
Why?
|
| Myocardium | 1 | 2018 | 1180 | 0.100 |
Why?
|
| Airway Obstruction | 1 | 2014 | 274 | 0.100 |
Why?
|
| Risk Factors | 3 | 2019 | 17855 | 0.090 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2018 | 1337 | 0.090 |
Why?
|
| Preoperative Care | 2 | 2018 | 1581 | 0.090 |
Why?
|
| Dyspnea | 1 | 2013 | 420 | 0.090 |
Why?
|
| Pyridines | 1 | 2017 | 1313 | 0.090 |
Why?
|
| Biopsy | 2 | 2015 | 3491 | 0.090 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2013 | 260 | 0.080 |
Why?
|
| Retrospective Studies | 6 | 2022 | 39922 | 0.080 |
Why?
|
| Biopsy, Needle | 1 | 2013 | 1381 | 0.080 |
Why?
|
| Female | 15 | 2020 | 148790 | 0.080 |
Why?
|
| Radiosurgery | 1 | 2018 | 1389 | 0.080 |
Why?
|
| Pyrazoles | 1 | 2017 | 1551 | 0.080 |
Why?
|
| Stents | 1 | 2014 | 1002 | 0.080 |
Why?
|
| Treatment Outcome | 4 | 2017 | 33811 | 0.070 |
Why?
|
| Breast Neoplasms | 3 | 2017 | 16242 | 0.070 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2018 | 2178 | 0.070 |
Why?
|
| Kidney Diseases | 1 | 2012 | 679 | 0.070 |
Why?
|
| Prognosis | 3 | 2016 | 22520 | 0.070 |
Why?
|
| Aged | 10 | 2020 | 73534 | 0.070 |
Why?
|
| Proton Therapy | 1 | 2016 | 1637 | 0.060 |
Why?
|
| Esophagus | 2 | 2021 | 562 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2018 | 6762 | 0.060 |
Why?
|
| Reproducibility of Results | 4 | 2017 | 6193 | 0.060 |
Why?
|
| Aged, 80 and over | 5 | 2017 | 31084 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 7643 | 0.050 |
Why?
|
| Sensitivity and Specificity | 3 | 2017 | 5157 | 0.050 |
Why?
|
| Adult | 7 | 2020 | 81960 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2017 | 10402 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 5595 | 0.040 |
Why?
|
| Quebec | 1 | 2018 | 20 | 0.040 |
Why?
|
| Arginine Vasopressin | 1 | 2018 | 66 | 0.040 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2018 | 398 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2018 | 747 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2018 | 9281 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2017 | 253 | 0.030 |
Why?
|
| Immunotherapy | 2 | 2021 | 3557 | 0.030 |
Why?
|
| Metals | 1 | 2016 | 147 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 14638 | 0.030 |
Why?
|
| Bronchial Diseases | 1 | 2014 | 46 | 0.030 |
Why?
|
| Ultrasonography, Mammary | 1 | 2017 | 387 | 0.030 |
Why?
|
| Tracheal Diseases | 1 | 2014 | 36 | 0.030 |
Why?
|
| Young Adult | 1 | 2013 | 22219 | 0.030 |
Why?
|
| Prostheses and Implants | 1 | 2016 | 291 | 0.030 |
Why?
|
| Papilloma | 1 | 2013 | 86 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2014 | 374 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 2300 | 0.030 |
Why?
|
| Liver | 1 | 2022 | 3056 | 0.030 |
Why?
|
| Hamartoma | 1 | 2013 | 92 | 0.030 |
Why?
|
| Breast Diseases | 1 | 2014 | 200 | 0.020 |
Why?
|
| Hemangioma | 1 | 2013 | 160 | 0.020 |
Why?
|
| Observer Variation | 1 | 2014 | 709 | 0.020 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2014 | 382 | 0.020 |
Why?
|
| Equipment Design | 1 | 2014 | 1207 | 0.020 |
Why?
|
| Logistic Models | 1 | 2018 | 3429 | 0.020 |
Why?
|
| Carcinoma, Small Cell | 1 | 2013 | 426 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2014 | 557 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 2016 | 1330 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2018 | 2068 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 4053 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2018 | 2376 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 4964 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2015 | 2033 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2016 | 4020 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 5318 | 0.020 |
Why?
|
| Mutation | 2 | 2018 | 15905 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 2395 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 10267 | 0.020 |
Why?
|
| Palliative Care | 1 | 2017 | 2175 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 9460 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 5099 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 6257 | 0.010 |
Why?
|
| Survival Rate | 1 | 2016 | 12527 | 0.010 |
Why?
|
| Algorithms | 1 | 2013 | 3906 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 10713 | 0.010 |
Why?
|
| Adolescent | 1 | 2017 | 32684 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 16719 | 0.010 |
Why?
|
| Child | 1 | 2013 | 30558 | 0.010 |
Why?
|